SVB Leerink Maintains Outperform on Biogen, Raises Price Target to $310

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $270 to $310.

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $270 to $310.

Total
0
Shares
Related Posts
Read More

Why Strong Global Stock Is Soaring

Strong Global Entertainment, Inc. shares are trading higher Monday after the company announced the proposed acquisition of Strong/MDI Screen Systems, Inc. by FG Acquisition Corp. In connection with the closing of the acquisition, the corporation intends to rename itself Saltire Holdings, Ltd.

SGE